I share my investment portfolio, the instruments I use, the best timing to invest, and the strategies I apply.
In January 2026, my public portfolio focused on consolidating “AI-driven operational efficiency” theses, specifically through an aggressive increase in Constellation Software (CSU), which now represents 34.5% of the total weight. Despite recent volatility in assets like Bitcoin (IB1T) and CSU’s technical correction, new strategic entries into Microsoft (MSFT) and Ferrari (RACE) aim to balance the […]
Microsoft (MSFT) remains the cornerstone of the global digital economy, reporting $281.7 billion in revenue for FY2025 and a 17% growth rate in Q2 2026. With an operating margin of 45.6% and an infrastructure-level lead in AI through Azure and its 49% stake in OpenAI, the company justifies its 27.5x P/E ratio. The recent 20%
Investing in Ferrari (RACE) stock in 2026 represents a high-conviction bet on the resilience of absolute luxury. Following a technical correction of over 40% from its highs, the company offers attractive valuation multiples (P/E) relative to its historical performance. With EBITDA margins exceeding 38%, an order book stretching into 2027, and a unique immunity to
As of January 2026, navigating the global equity market requires a surgical distinction between price and value. This analysis evaluates six industry leaders: Microsoft (MSFT), Amazon (AMZN), Hermès (RMS), Meta (META), Mastercard (MA), and Ferrari (RACE). While MSFT, AMZN, and RMS currently trade at premiums requiring technical corrections (PERs of 28–42), META, MA, and RACE
As of 2026, Constellation Software Inc. (CSU) stands as the premier Vertical Market Software (VMS) consolidator. Unlike horizontal giants like Adobe or Salesforce, CSU focuses on mission-critical niches with high switching costs and low churn. With a historical ROIC exceeding 20% and a disciplined, decentralized M&A engine, CSU thrives in a high-interest, AI-driven environment. This
In 2026, Novo Nordisk (NVO) remains the undisputed leader in the GLP-1 market, bolstered by the record-breaking launch of its oral obesity pill. With a projected revenue CAGR of 11.41% and EPS growth of 13.93% through 2028, the company’s fundamentals are unmatched. Currently trading at a P/E ratio below 17—well under its 5-year median of
